Outcomes of Patients With Acute Coronary Syndrome and Previous Coronary Artery Bypass Grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] Trials)

American Journal of Cardiology

Volumn 102, Issue 5, 2008, Pages 552-558

  Brilakis, Emmanouil S ^a,b   de Lemos, James A ^a   Cannon, Christopher P ^c   Wiviott, Stephen D ^c   Murphy, Sabina A ^c   Morrow, David A ^c   Sabatine, Marc S ^c   Banerjee, Subhash ^a,b   Blazing, Michael A ^d   Califf, Robert M ^d   Braunwald, Eugene ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; ENOXAPARIN; GATIFLOXACIN; HEPARIN; PRAVASTATIN; SIMVASTATIN; TIROFIBAN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLOOD CLOT LYSIS; CARDIAC PATIENT; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HIGH RISK POPULATION; HOSPITAL READMISSION; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STROKE;

CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE CARE; PRAVASTATIN; PYRROLES; RETROSPECTIVE STUDIES; SIMVASTATIN; SYNDROME; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME; TYROSINE;

EID: 50949117228     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.04.024     Document Type: Article

References (29)

1. Sabik III J.F., Blackstone E.H., Gillinov A.M., Smedira N.G., and Lytle B.W. Occurrence and risk factors for reintervention after coronary artery bypass grafting. Circulation 114 suppl (2006) I454-I460
2. Savage M.P., Douglas Jr. J.S., Fischman D.L., Pepine C.J., King III S.B., Werner J.A., Bailey S.R., Overlie P.A., Fenton S.H., Brinker J.A., Leon M.B., and Goldberg S. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 337 (1997) 740-747
3. de Jaegere P.P., van Domburg R.T., Feyter P.J., Ruygrok P.N., van der Giessen W.J., van den Brand M.J., and Serruys P.W. Long-term clinical outcome after stent implantation in saphenous vein grafts. J Am Coll Cardiol 28 (1996) 89-96
4. Keeley E.C., Velez C.A., O'Neill W.W., and Safian R.D. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol 38 (2001) 659-665
5. Morrison D.A., Sethi G., Sacks J., Henderson W.G., Grover F., Sedlis S., and Esposito R. Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. J Am Coll Cardiol 40 (2002) 1951-1954
6. Weintraub W.S., Jones E.L., Morris D.C., King III S.B., Guyton R.A., and Craver J.M. Outcome of reoperative coronary bypass surgery versus coronary angioplasty after previous bypass surgery. Circulation 95 (1997) 868-877
7. Okrainec K., Platt R., Pilote L., and Eisenberg M.J. Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery: a review of randomized controlled trials. J Am Coll Cardiol 45 (2005) 177-184
8. Motwani J.G., and Topol E.J. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97 (1998) 916-931
9. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 336 (1997) 153-162
10. Frick M.H., Syvanne M., Nieminen M.S., Kauma H., Majahalme S., Virtanen V., Kesaniemi Y.A., Pasternack A., and Taskinen M.R. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 96 (1997) 2137-2143
11. Blankenhorn D.H., Johnson R.L., Nessim S.A., Azen S.P., Sanmarco M.E., and Selzer R.H. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Control Clin Trials 8 (1987) 356-387
12. Cashin-Hemphill L., Mack W.J., Pogoda J.M., Sanmarco M.E., Azen S.P., and Blankenhorn D.H. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 264 (1990) 3013-3017
13. Azen S.P., Mack W.J., Cashin-Hemphill L., LaBree L., Shircore A.M., Selzer R.H., Blankenhorn D.H., and Hodis H.N. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 93 (1996) 34-41
14. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., Skene A.M., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
15. de Lemos J.A., Blazing M.A., Wiviott S.D., Lewis E.F., Fox K.A.A., White H.D., Rouleau J.-L., Pedersen T.R., Gardner L.H., Mukherjee R., et al., A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z Trial. JAMA 292 (2004) 1307-1316
16. Cannon C.P., Braunwald E., McCabe C.H., Grayston J.T., Muhlestein B., Giugliano R.P., Cairns R., and Skene A.M. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 352 (2005) 1646-1654
17. Blazing M.A., de Lemos J.A., White H.D., Fox K.A., Verheugt F.W., Ardissino D., DiBattiste P.M., Palmisano J., Bilheimer D.W., Snapinn S.M., et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 292 (2004) 55-64
18. Blazing M.A., De Lemos J.A., Dyke C.K., Califf R.M., Bilheimer D., and Braunwald E. The A-to-Z Trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 142 (2001) 211-217
19. Waters D.D., Walling A., Roy D., and Theroux P. Previous coronary artery bypass grafting as an adverse prognostic factor in unstable angina pectoris. Am J Cardiol 58 (1986) 465-469
20. Wiseman A., Waters D.D., Walling A., Pelletier G.B., Roy D., and Theroux P. Long-term prognosis after myocardial infarction in patients with previous coronary artery bypass surgery. J Am Coll Cardiol 12 (1988) 873-880
21. Kleiman N.S., Anderson H.V., Rogers W.J., Theroux P., Thompson B., and Stone P.H. Comparison of outcome of patients with unstable angina and non-Q-wave acute myocardial infarction with and without prior coronary artery bypass grafting (Thrombolysis In Myocardial Ischemia III Registry). Am J Cardiol 77 (1996) 227-231
22. Mathew V., Berger P.B., Lennon R.J., Gersh B.J., and Holmes Jr. D.R. Comparison of percutaneous interventions for unstable angina pectoris in patients with and without previous coronary artery bypass grafting. Am J Cardiol 86 (2000) 931-937
23. Labinaz M., Kilaru R., Pieper K., Marso S.P., Kitt M.M., Simoons M.L., Califf R.M., Topol E.J., Armstrong P.W., and Harrington R.A. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. Circulation 105 (2002) 322-327
24. Servoss S.J., Wan Y., Snapinn S.M., DiBattiste P.M., Zhao X.Q., Theroux P., Jang I.K., and Januzzi Jr. J.L. Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. Am J Cardiol 93 (2004) 843-847
25. Kugelmass A.D., Sadanandan S., Lakkis N., Dibattiste P.M., Robertson D.H., Demopoulos L.A., Gibson C.M., Weintraub W.S., Murphy S.A., and Cannon C.P. Early invasive strategy improves outcomes in patients with acute coronary syndrome with previous coronary artery bypass graft surgery: a report from TACTICS-TIMI 18. Crit Pathways Cardiol 5 (2006) 167-172
26. Gurfinkel E., Perez de la Hozb R., Britob V.M., Durontoa E., Dabbousc O.H., Gorec J.M., and Anderson F.A. Invasive vs non-invasive treatment in acute coronary syndromes and prior bypass surgery. Int J Cardiol 119 (2007) 65-72
27. Knatterud G.L., Rosenberg Y., Campeau L., Geller N.L., Hunninghake D.B., Forman S.A., Forrester J.S., Gobel F.L., Herd J.A., Hickey A., et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation 102 (2000) 157-165
28. Shah S.J., Waters D.D., Barter P., Kastelein J.J., Shepherd J., Wenger N.K., DeMicco D.A., Breazna A., and LaRosa J.C. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol 51 (2008) 1938-1943
29. Wiviott S.D., de Lemos J.A., Cannon C.P., Blazing M., Murphy S.A., McCabe C.H., Califf R., and Braunwald E. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 113 (2006) 1406-1414